title: Antidepressant-Induced Sexual Dysfunction among Newer Antidepressants in a Naturalistic Setting.
abstract: OBJECTIVE
  Antidepressants used to treat depression are frequently associated with sexual dysfunction. Sexual side effects affect the patient's quality of life and, in long-term treatment, can lead to non-compliance and relapse. However, studies covering many antidepressants with differing mechanisms of action were scarce. The present study assessed and compared the incidence of sexual dysfunction among different antidepressants in a naturalistic setting.
  
  
  METHODS
  Participants were married patients diagnosed with depression, per DSM-IV diagnostic criteria, who had been taking antidepressants for more than 1 month. We assessed the participants via the Arizona Sexual Experiences Scale (ASEX), Beck Depression Inventory (BDI), and State-Trait Anxiety Inventory (STAI), and assessed their demographic variables, types and dosages of antidepressants, and duration of antidepressant use via their medical records.
  
  
  RESULTS
  One hundred and one patients (46 male, 55 female, age 42.2+/-7 years) completed the instruments. Thirteen were taking fluoxetine (mean dose 21.3+/-8.5 mg/day), 24 were taking paroxetine (mean dose 20.4+/-7.2 mg/day), 20 taking citalopram (mean dose 22.1+/-6.5 mg/day), 22, venlafaxine (mean dose 115.7+/-53.2 mg/day) and 22, mirtazapine (mean dose 18+/-8.7 mg/day). Mean ages, sex ratios, and BDI and STAI scores did not differ significantly across antidepressants. A substantial number of participants (46.5%, n=47) experienced sexual dysfunction. The prevalence of sexual dysfunction differed across drugs: citalopram 60% (n=12), venlafaxine 54.5% (n=12), paroxetine 54.2% (n=13), fluoxetine 46.2% (n=6), and mirtazapine 18.2% (n=4). Regression analyses revealed the significant factors for sexual dysfunction were being female, total scores on the BDI and SAI, and type of antidepressant (F=4.92, p<0.0001). Of the antidepressants, the mirtarzapine group's total ASEX score was significantly lower than the scores of the citalopram, fluoxetine, and paroxetine groups.
  
  
  CONCLUSIONS
  The incidence of sexual dysfunction was substantially high during antidepressant treatment. The incidence of sexual dysfunction differed among antidepressants having different mechanisms of action. Our study suggests the need for clinicians to consider the impact of pharmacotherapy on patients' sexual functioning in the course of treatment with antidepressants.
authors.affiliation: Department of Psychiatry, College of Medicine, The Catholic University of Korea, Seoul, Korea.
authors.forename: Kyoung-Uk
authors.initials: KU
authors.lastname: Lee
authors.forename: Young Min
authors.initials: YM
authors.lastname: Lee
authors.forename: Ji-Min
authors.initials: JM
authors.lastname: Nam
authors.forename: Hae-Kook
authors.initials: HK
authors.lastname: Lee
authors.forename: Yong-Sil
authors.initials: YS
authors.lastname: Kweon
authors.forename: Chung Tai
authors.initials: CT
authors.lastname: Lee
authors.forename: Tae-Youn
authors.initials: TY
authors.lastname: Jun
references.citation: Int J Impot Res. 1996 Jun;8(2):47-52
references.pmid: 8858389
references.citation: J Sex Marital Ther. 1996 Fall;22(3):209-17
references.pmid: 8880654
references.citation: J Clin Psychiatry. 1998;59 Suppl 8:39-44; discussion 45-6
references.pmid: 9707161
references.citation: Curr Womens Health Rep. 2002 Jun;2(3):182-7
references.pmid: 12099193
references.citation: Ann Pharmacother. 2002 Oct;36(10):1577-89
references.pmid: 12243609
references.citation: Br J Pharmacol. 2001 Nov;134(6):1190-4
references.pmid: 11704638
references.citation: Expert Opin Pharmacother. 2000 Jul;1(5):903-16
references.pmid: 11249499
references.citation: J Clin Psychiatry. 1999;60 Suppl 17:14-7; discussion 46-8
references.pmid: 10446736
references.citation: Fam Pract. 1998 Dec;15(6):519-24
references.pmid: 10078790
references.citation: Actas Luso Esp Neurol Psiquiatr Cienc Afines. 1996 Nov-Dec;24(6):311-21
references.pmid: 9054202
references.citation: J Clin Psychiatry. 2001;62 Suppl 3:10-21
references.pmid: 11229449
references.citation: J Clin Psychopharmacol. 1998 Aug;18(4):274-81
references.pmid: 9690692
references.citation: Arch Gen Psychiatry. 1961 Jun;4:561-71
references.pmid: 13688369
references.citation: Neuropsychopharmacology. 2004 Sep;29(9):1699-703
references.pmid: 15127082
references.citation: J Clin Psychiatry. 1995;56 Suppl 6:12-21
references.pmid: 7649968
references.citation: Int Clin Psychopharmacol. 1998 Jul;13 Suppl 6:S27-33
references.pmid: 9728672
references.citation: J Clin Psychiatry. 2000 Apr;61(4):276-81
references.pmid: 10830148
references.citation: J Sex Marital Ther. 2000 Jan-Mar;26(1):25-40
references.pmid: 10693114
references.citation: J Clin Psychiatry. 2002;63 Suppl 5:13-6; discussion 23-5
references.pmid: 11964136
references.citation: J Clin Psychiatry. 1998;59 Suppl 4:5-14
references.pmid: 9554316
references.citation: J Psychopharmacol. 1997;11(1):72-82
references.pmid: 9097897
references.citation: Expert Opin Drug Saf. 2004 Sep;3(5):457-70
references.pmid: 15335301
references.citation: J Clin Psychiatry. 2001 Feb;62(2):80-1
references.pmid: 11247105
references.citation: J Clin Epidemiol. 1997 Oct;50(10):1129-36
references.pmid: 9368521